AUPH

Aurinia Pharmaceuticals reported a loss per share of $0.25, which was below expectations. Despite this miss, the stock saw a slight increase of 0.24%, indicating that investors may have had lower expectations or are optimistic about future developments. The lack of revenue data and management commentary leaves some uncertainty about the company's current performance and future outlook.